Highlights From CMSC 2023
Ofatumumab in MS presentations
Real-world Satisfaction and Experience with Injection and Autoinjector Device for Ofatumumab indicated for Multiple Sclerosis
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis
Real world persistence and adherence to ofatumumab versus other self injectable disease modifying therapies (DMTs) in patients with multiple sclerosis
BE2306301856